1. Nanocarrier-based systems for targeted and site specific therapeutic delivery. Majumber et al. 2019. Advanced Drug Delivery Reviews

One of the major problems of the current IBD therapies is that they produce side effects when they are delivered in a systemic way like oral administration. Thus, there is a need to develop targeted delivery strategies that affect only the body area that endures the disease. Nanoparticles stand as a potential solution to reduce these side effects, as they can carry the therapeutic molecule to the place of interest. Nevertheless, to enhance nanoparticles ability to target only the affected areas they should be combined with specific targeting strategies or local administration.

Read this review to discover the main advantages and limitations of nanoparticles as delivery system, both by themselves or combined with different features such as supramolecular gels or therapeutic cells that tune the targeted delivery. This mixed delivery strategy may become the future of the treatment of diseases like IBD. To the publication>

2. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics. Kulkarny et al. 2019. Accounts of Chemical Research 52 (9), 2435-2444

Nucleic acid therapies stand as an attractive option to treat a wide range of diseases. Silencing gene expression using synthetic molecules called siRNAs is one of the most potent strategies and it has been considered to treat diseases such as IBD. However, siRNA molecules are easily degraded by enzymes and their chemical properties impair their ability to go inside the cells to make their effect. Therefore, siRNAs must be administered using delivery strategies such as lipid nanoparticles (LNP) that carry and protect these molecules.

In this review, the authors provide an overview of the latest advances on LNP technology. More concretely, the review discusses the best LNP formulations to improve siRNA encapsulation and gives insight about the future of these strategy to deliver genetic-based drugs. To the publicacion>